ROBERT STOVER
Pharmacy at Pleasantdale Dr, Lewis Center, OH
License number
Ohio 03-2-26561
Category
Pharmacy
Type
Pharmacist
Address
Address
2905 Pleasantdale Dr, Lewis Center, OH 43035
Phone
(740) 972-3478
Professional information
Methods And Formulations For Treating Ineffective Or Decreased Esophagal Motility
US Patent:
2013016, Jun 27, 2013
Filed:
Feb 20, 2013
Appl. No.:
13/771334
Inventors:
Robert C. Stover - Lewis Center OH, US
International Classification:
A61K 31/325
US Classification:
514478
Abstract:
Disclosed embodiments describe pharmaceutical compositions and methods for treating ineffective esophageal motility in which bethanechol and pharmaceutically acceptable absorption enhancers including bile acids and mixtures thereof are topically introduced to the esophagus. Therapeutically effective amounts of bethanechol are delivered while reducing or eliminating parasympathetic nervous system side effects normally associated with systemic bethanechol delivery.
Methods And Formulations For Treating Ineffective Or Decreased Esophageal Motility
US Patent:
8143314, Mar 27, 2012
Filed:
Sep 15, 2008
Appl. No.:
12/210995
Inventors:
Robert Carl Stover - Lewis Center OH, US
International Classification:
A01N 33/12
US Classification:
514642
Abstract:
Pharmaceutical compositions and methods for treating ineffective esophageal motility in which bethanechol and pharmaceutically acceptable absorption enhancers comprising bile acids and mixtures thereof are topically introduced to the esophagus. Therapeutically effective amounts of bethanechol are delivered while reducing or eliminating parasympathetic nervous system side effects normally associated with systemic bethanechol delivery.
Methods And Formulations For Treating Ineffective Or Decreased Esophagal Motility
US Patent:
8383684, Feb 26, 2013
Filed:
Mar 26, 2012
Appl. No.:
13/430266
Inventors:
Robert Carl Stover - Lewis Center OH, US
Assignee:
Bethanamist LLC - Lewis Center OH
International Classification:
A01N 33/12
US Classification:
514642
Abstract:
Disclosed embodiments describe pharmaceutical compositions and methods for treating ineffective esophageal motility in which bethanechol and pharmaceutically acceptable absorption enhancers including bile acids and mixtures thereof are topically introduced to the esophagus. Therapeutically effective amounts of bethanechol are delivered while reducing or eliminating parasympathetic nervous system side effects normally associated with systemic bethanechol delivery.